Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, bought additional company stock in the open market. He purchased 2,521 shares of Common Stock at a price of $1.15 per share. Following this transaction, he directly holds 130,925 shares, increasing his personal stake in the company.
IRIDEX CORP Chief Financial Officer Romeo R. Dizon bought additional company stock in the open market. He purchased 2,400 shares of common stock at a price of $1.17 per share. After this transaction, he directly owns a total of 128,404 IRIDEX common shares.
IRIDEX CORP President and CEO Patrick Mercer reported a tax-related share disposition on Common Stock. On this Form 4, 19,233 shares were delivered at $1.01 per share to cover tax obligations, and he now directly holds 372,774 shares of Common Stock.
IRIDEX Corp Chief Financial Officer Romeo R. Dizon reported an open-market purchase of 5,004 shares of common stock at $1.00 per share. Following this transaction, he directly holds 126,004 shares of IRIDEX common stock, modestly increasing his personal stake in the company.
IRIDEX Corporation reported a smaller quarterly loss on essentially flat revenue. For the three months ended April 4, 2026, revenue was $11.8 million versus $11.9 million a year earlier, as higher glaucoma and "other" sales offset lower retina product revenue.
Gross profit declined to $4.7 million and gross margin slipped to 40.2% from 42.5%, mainly from higher manufacturing and tariff-related costs during a transition to lower-cost contract manufacturers. Operating expenses fell slightly, with general and administrative costs down due to lower consulting and deal-related legal spending.
Net loss improved to $0.5 million from $1.7 million, helped by the absence of the prior-year $1.3 million loss on extinguishment of a convertible note. Cash and cash equivalents were $4.6 million and working capital was $11.8 million at quarter end. Management believes existing liquidity is sufficient for at least the next 12 months.
Iridex Corporation reported first-quarter 2026 results, with total revenue of $11.8 million, down 1% from the prior-year period. Cyclo G6 product revenue grew 14% to $3.6 million, while retina product revenue declined to $5.8 million from $6.6 million, reflecting international supply and regulatory challenges.
Gross profit was $4.7 million, a 40% margin, compared with $5.0 million and a 43% margin a year earlier, mainly due to higher manufacturing and tariff-related costs. Operating expenses fell 4% to $5.1 million, driven by lower consulting, legal, and administrative costs, leading to a reduced net loss of $0.5 million, or $0.03 per share, versus $1.7 million, or $0.10 per share, last year.
Adjusted EBITDA was $0.3 million, down from $0.4 million in the prior-year quarter. Cash and cash equivalents were $4.6 million as of April 4, 2026. Iridex reaffirmed full-year 2026 revenue guidance of $51 million to $53 million and continues to expect positive operating cash flow for the year despite regional market disruptions.
IRIDEX Corporation is asking stockholders to vote at its annual meeting on June 12, 2026 on three key items: electing five directors, ratifying BPM LLP as independent auditor for fiscal 2026, and approving an advisory Say‑on‑Pay vote on executive compensation.
Holders of 17,395,350 shares of common stock get one vote per share, and holders of 600,000 shares of Series B preferred stock get five votes per share as of the April 17, 2026 record date. The board is currently five members, with Patrick Mercer serving as President, Chief Executive Officer and Chief Operating Officer, and four independent directors chairing committees overseeing audit, compensation, nominations, and strategy.
The proxy details 2025 pay, including total compensation of about $901,900 for Mr. Mercer and incentive bonuses tied to a short‑term plan that paid roughly 99.5% of target based on sales, gross profit and operating goals. Stockholders are encouraged to vote via internet, telephone or mail, and may attend and vote in person in Mountain View, California.
IRIDEX CORP reported that major shareholder Novel Inspiration International Co., Ltd. received 87,949 shares of Common Stock on April 1, 2026. These shares were issued as a quarterly interest payment on a Convertible Promissory Note dated March 19, 2025.
After this stock-for-interest transaction, Novel Inspiration holds a total of 439,432 IRIDEX common shares directly. The Form 4 is filed jointly with Shih-Yao David Lin, who is the sole officer, director and stockholder of Novel Inspiration, but the shares are owned by the company, not by Lin personally.
IRIDEX Corporation, an ophthalmic medical technology company, reports that total revenues reached $52.7 million in fiscal 2025, up from $48.7 million in 2024, while net loss narrowed to $4.4 million from $8.9 million. The company sells laser consoles and single-use probes for glaucoma and retinal diseases, leveraging its MicroPulse and Endpoint Management technologies. It relies heavily on international sales and a strategic distribution partnership with Topcon, while facing macroeconomic pressures, regulatory complexity and supply-chain risks. IRIDEX also entered into a $4.0 million convertible note with Novel Inspiration International, with the option for up to $10.0 million in additional notes, adding new debt and potential future equity dilution.